GSK: starts study of once-monthly injectable HIV drug
(CercleFinance.com) - GSK's ViiV Healthcare said it has started the first-ever study to evaluate implementing its once-monthly injectable HIV treatment in clinical practice.
This means that a team from ViiV Healthcare will work with clinical staff at several sites across the US during the one-year study to find the most practical and efficient ways to implement the regimen.
ViiV's long-acting injectable regimen has been granted a priority review status by the FDA, with a target approval date set for this year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
This means that a team from ViiV Healthcare will work with clinical staff at several sites across the US during the one-year study to find the most practical and efficient ways to implement the regimen.
ViiV's long-acting injectable regimen has been granted a priority review status by the FDA, with a target approval date set for this year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.